{
    "clinical_study": {
        "@rank": "163382", 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.\n\n      PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating\n      patients who have refractory metastatic melanoma."
        }, 
        "brief_title": "Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma", 
        "completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "condition": "Melanoma (Skin)", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine whether an immunologic response can be obtained after administration of ESO-1\n           peptide vaccine comprising class I , II, or both peptides in HLA-A*201 or HLA-DPB1*04\n           positive patients with refractory metastatic melanoma expressing ESO-1.\n\n        -  Determine the toxicity of this vaccine in these patients.\n\n        -  Determine whether prior immunization with this vaccine results in increased clinical\n           responsiveness in patients treated with interleukin-2.\n\n      OUTLINE: Patients are assigned to 1 of 3 groups according to HLA type.\n\n        -  Group 1 (HLA-A*201 and HLA-DPB1*04 positive): Patients receive ESO-1 peptide vaccine\n           comprising class I (ESO-1:157-165 [165V]) and class II (ESO-1:161-180) peptides\n           subcutaneously once every 3 weeks for 4 courses in the absence of disease progression\n           or unacceptable toxicity.\n\n        -  Group 2 (HLA-A*201 positive and HLA-DPB1*04 negative):Patients receive ESO-1 peptide\n           vaccine as in group I comprising class I peptide only.\n\n        -  Group 3 (HLA-A*201 negative and HLA-DPB1*04 positive):Patients receive ESO-1 peptide\n           vaccine as in group I comprising class II peptide only.\n\n      Patients who develop disease progression discontinue vaccinations and receive high-dose\n      interleukin (IL-2) IV over 15 minutes every 8 hours for up to 4 days (maximum of 12 doses).\n      Treatment with IL-2 repeats every 10-14 days for 4 courses in the absence of disease\n      progression (after at least 2 courses) or unacceptable toxicity.\n\n      Patients who have stable disease or a mixed or partial response to vaccination or IL-2\n      therapy may be eligible for additional vaccine therapy. Patients who have a complete\n      response to vaccine therapy are eligible for 1 additional treatment.\n\n      Patients are followed at 3 weeks.\n\n      PROJECTED ACCRUAL: A total of 45-90 patients (15-30 per treatment group) will be accrued for\n      this study within 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of metastatic melanoma that expresses ESO-1 antigen\n\n          -  Must have progressed during prior standard treatment\n\n          -  Measurable or evaluable disease\n\n          -  HLA-A*201 or HLA-DPB1*04 positive\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  16 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Platelet count at least 90,000/mm^3\n\n        Hepatic:\n\n          -  SGOT and SGPT less than 3 times normal\n\n          -  Bilirubin no greater than 1.6 mg/dL (3.0 mg/dL for patients with Gilbert's syndrome)\n\n          -  Hepatitis B surface antigen negative\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No cardiac ischemia*\n\n          -  No myocardial infarction*\n\n          -  No cardiac arrhythmias* NOTE: *For interleukin-2 (IL-2) administration\n\n        Pulmonary:\n\n          -  No obstructive or restrictive pulmonary disease (for IL-2 administration)\n\n        Immunologic:\n\n          -  No autoimmune disease\n\n          -  No active primary or secondary immunodeficiency\n\n          -  HIV negative\n\n          -  No active systemic infections\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No other active major medical illness (for IL-2 administration)\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior ESO-1 immunization\n\n        Chemotherapy:\n\n          -  Recovered from any prior chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent systemic steroid therapy\n\n        Radiotherapy:\n\n          -  Recovered from any prior radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 3 weeks since any prior systemic therapy for cancer\n\n          -  No other concurrent systemic therapy for cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00006491", 
            "nct_id": "NCT00020397", 
            "org_study_id": "CDR0000068403", 
            "secondary_id": [
                "NCI-01-C-0032", 
                "NCI-2390"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "NY-ESO-1 peptide vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "aldesleukin", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aldesleukin"
        }, 
        "keyword": [
            "recurrent melanoma", 
            "stage IV melanoma"
        ], 
        "lastchanged_date": "June 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NCI-01-C-0032"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892-1182"
                }, 
                "name": "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen", 
        "overall_official": {
            "affiliation": "NCI - Surgery Branch", 
            "last_name": "Steven A. Rosenberg, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00020397"
        }, 
        "results_reference": {
            "PMID": "15534491", 
            "citation": "Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov-Dec;27(6):472-7."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2005"
    }, 
    "geocoordinates": {
        "Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support": "38.985 -77.095"
    }
}